Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：399頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014’, provides an overview of the Amyotrophic Lateral Sclerosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014’, provides an overview of the Amyotrophic Lateral Sclerosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 6
Amyotrophic Lateral Sclerosis Overview 7
Therapeutics Development 8
Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 10
Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 17
Amyotrophic Lateral Sclerosis - Pipeline Products Glance 20
Amyotrophic Lateral Sclerosis - Products under Development by Companies 24
Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 30
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 34
Amyotrophic Lateral Sclerosis - Therapeutics Assessment 95
Drug Profiles 110
Amyotrophic Lateral Sclerosis - Recent Pipeline Updates 317
Amyotrophic Lateral Sclerosis - Dormant Projects 370
Amyotrophic Lateral Sclerosis - Discontinued Products 372
Amyotrophic Lateral Sclerosis - Product Development Milestones 373
Appendix 381
List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2014 25
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 28
Number of Products under Development by Companies, H1 2014 (Contd..1) 29
Number of Products under Development by Companies, H1 2014 (Contd..2) 30
Number of Products under Development by Companies, H1 2014 (Contd..3) 31
Number of Products under Development by Companies, H1 2014 (Contd..4) 32
Number of Products under Development by Companies, H1 2014 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2014 35
Comparative Analysis by Late Stage Development, H1 2014 37
Comparative Analysis by Clinical Stage Development, H1 2014 38
Comparative Analysis by Early Stage Development, H1 2014 39
Comparative Analysis by Unknown Stage Development, H1 2014 40
Products under Development by Companies, H1 2014 41
Products under Development by Companies, H1 2014 (Contd..1) 42
Products under Development by Companies, H1 2014 (Contd..2) 43
Products under Development by Companies, H1 2014 (Contd..3) 44
Products under Development by Companies, H1 2014 (Contd..4) 45
Products under Development by Companies, H1 2014 (Contd..5) 46
Products under Investigation by Universities/Institutes, H1 2014 47
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 48
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 49
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 50
Amyotrophic Lateral Sclerosis - Pipeline by Genzyme Corporation, H1 2014 51
Amyotrophic Lateral Sclerosis - Pipeline by Biogen Idec Inc., H1 2014 52
Amyotrophic Lateral Sclerosis - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 53
Amyotrophic Lateral Sclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 54
Amyotrophic Lateral Sclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 55
Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica plc, H1 2014 56
Amyotrophic Lateral Sclerosis - Pipeline by Sangamo BioSciences, Inc., H1 2014 57
Amyotrophic Lateral Sclerosis - Pipeline by Amorfix Life Sciences Ltd., H1 2014 58
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H1 2014 59
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 60
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 61
Amyotrophic Lateral Sclerosis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 62
Amyotrophic Lateral Sclerosis - Pipeline by TCA Cellular Therapy, LLC, H1 2014 63
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2014 64
Amyotrophic Lateral Sclerosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 65
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2014 66
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H1 2014 67
Amyotrophic Lateral Sclerosis - Pipeline by Nutra Pharma Corporation, H1 2014 68
Amyotrophic Lateral Sclerosis - Pipeline by Paladin Labs Inc., H1 2014 69
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Incorporated, H1 2014 70
Amyotrophic Lateral Sclerosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 71
Amyotrophic Lateral Sclerosis - Pipeline by D-Pharm Ltd., H1 2014 72
Amyotrophic Lateral Sclerosis - Pipeline by Scynexis, Inc., H1 2014 73
Amyotrophic Lateral Sclerosis - Pipeline by Snowdon Inc., H1 2014 74
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H1 2014 75
Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2014 76
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2014 77
Amyotrophic Lateral Sclerosis - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 78
Amyotrophic Lateral Sclerosis - Pipeline by Knopp Biosciences LLC, H1 2014 79
Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H1 2014 80
Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H1 2014 81
Amyotrophic Lateral Sclerosis - Pipeline by AB Science, H1 2014 82
Amyotrophic Lateral Sclerosis - Pipeline by to-BBB technologies BV, H1 2014 83
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd., H1 2014 84
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2014 85
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H1 2014 86
Amyotrophic Lateral Sclerosis - Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2014 87
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H1 2014 88
Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corporation, H1 2014 89
Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H1 2014 90
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H1 2014 91
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2014 92
Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H1 2014 93
Amyotrophic Lateral Sclerosis - Pipeline by California Stem Cell, Inc., H1 2014 94
Amyotrophic Lateral Sclerosis - Pipeline by Varinel, Inc., H1 2014 95
Amyotrophic Lateral Sclerosis - Pipeline by ExSAR Corporation, H1 2014 96
Amyotrophic Lateral Sclerosis - Pipeline by Stealth Peptides Inc., H1 2014 97
Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H1 2014 98
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 99
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2014 100
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H1 2014 101
Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H1 2014 102
Amyotrophic Lateral Sclerosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2014 103
Amyotrophic Lateral Sclerosis - Pipeline by Bionure, H1 2014 104
Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 105
Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 106
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H1 2014 107
Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 108
Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H1 2014 109
Amyotrophic Lateral Sclerosis - Pipeline by Cellular Biomedicine Group, Inc., H1 2014 110
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H1 2014 111
Assessment by Monotherapy Products, H1 2014 112
Number of Products by Stage and Target, H1 2014 115
Number of Products by Stage and Mechanism of Action, H1 2014 119
Number of Products by Stage and Route of Administration, H1 2014 123
Number of Products by Stage and Molecule Type, H1 2014 126
Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H1 2014 334
Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2014 387
Amyotrophic Lateral Sclerosis - Discontinued Products, H1 2014 389
List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2014 25
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 34
Comparative Analysis by Late Stage Development, H1 2014 37
Comparative Analysis by Clinical Stage Development, H1 2014 38
Comparative Analysis by Early Stage Products, H1 2014 39
Assessment by Monotherapy Products, H1 2014 112
Number of Products by Top 10 Target, H1 2014 113
Number of Products by Stage and Top 10 Target, H1 2014 114
Number of Products by Top 10 Mechanism of Action, H1 2014 117
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 118
Number of Products by Top 10 Route of Administration, H1 2014 121
Number of Products by Stage and Top 10 Route of Administration, H1 2014 122
Number of Products by Top 10 Molecule Type, H1 2014 124
Number of Products by Stage and Top 10 Molecule Type, H1 2014 125
Table of Contents 2
Introduction 6
Amyotrophic Lateral Sclerosis Overview 7
Therapeutics Development 8
Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 10
Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 17
Amyotrophic Lateral Sclerosis - Pipeline Products Glance 20
Amyotrophic Lateral Sclerosis - Products under Development by Companies 24
Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 30
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 34
Amyotrophic Lateral Sclerosis - Therapeutics Assessment 95
Drug Profiles 110
Amyotrophic Lateral Sclerosis - Recent Pipeline Updates 317
Amyotrophic Lateral Sclerosis - Dormant Projects 370
Amyotrophic Lateral Sclerosis - Discontinued Products 372
Amyotrophic Lateral Sclerosis - Product Development Milestones 373
Appendix 381
List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2014 25
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 28
Number of Products under Development by Companies, H1 2014 (Contd..1) 29
Number of Products under Development by Companies, H1 2014 (Contd..2) 30
Number of Products under Development by Companies, H1 2014 (Contd..3) 31
Number of Products under Development by Companies, H1 2014 (Contd..4) 32
Number of Products under Development by Companies, H1 2014 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2014 35
Comparative Analysis by Late Stage Development, H1 2014 37
Comparative Analysis by Clinical Stage Development, H1 2014 38
Comparative Analysis by Early Stage Development, H1 2014 39
Comparative Analysis by Unknown Stage Development, H1 2014 40
Products under Development by Companies, H1 2014 41
Products under Development by Companies, H1 2014 (Contd..1) 42
Products under Development by Companies, H1 2014 (Contd..2) 43
Products under Development by Companies, H1 2014 (Contd..3) 44
Products under Development by Companies, H1 2014 (Contd..4) 45
Products under Development by Companies, H1 2014 (Contd..5) 46
Products under Investigation by Universities/Institutes, H1 2014 47
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 48
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 49
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 50
Amyotrophic Lateral Sclerosis - Pipeline by Genzyme Corporation, H1 2014 51
Amyotrophic Lateral Sclerosis - Pipeline by Biogen Idec Inc., H1 2014 52
Amyotrophic Lateral Sclerosis - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 53
Amyotrophic Lateral Sclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 54
Amyotrophic Lateral Sclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 55
Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica plc, H1 2014 56
Amyotrophic Lateral Sclerosis - Pipeline by Sangamo BioSciences, Inc., H1 2014 57
Amyotrophic Lateral Sclerosis - Pipeline by Amorfix Life Sciences Ltd., H1 2014 58
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H1 2014 59
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 60
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 61
Amyotrophic Lateral Sclerosis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 62
Amyotrophic Lateral Sclerosis - Pipeline by TCA Cellular Therapy, LLC, H1 2014 63
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2014 64
Amyotrophic Lateral Sclerosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 65
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2014 66
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H1 2014 67
Amyotrophic Lateral Sclerosis - Pipeline by Nutra Pharma Corporation, H1 2014 68
Amyotrophic Lateral Sclerosis - Pipeline by Paladin Labs Inc., H1 2014 69
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Incorporated, H1 2014 70
Amyotrophic Lateral Sclerosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 71
Amyotrophic Lateral Sclerosis - Pipeline by D-Pharm Ltd., H1 2014 72
Amyotrophic Lateral Sclerosis - Pipeline by Scynexis, Inc., H1 2014 73
Amyotrophic Lateral Sclerosis - Pipeline by Snowdon Inc., H1 2014 74
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H1 2014 75
Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2014 76
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2014 77
Amyotrophic Lateral Sclerosis - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 78
Amyotrophic Lateral Sclerosis - Pipeline by Knopp Biosciences LLC, H1 2014 79
Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H1 2014 80
Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H1 2014 81
Amyotrophic Lateral Sclerosis - Pipeline by AB Science, H1 2014 82
Amyotrophic Lateral Sclerosis - Pipeline by to-BBB technologies BV, H1 2014 83
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd., H1 2014 84
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2014 85
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H1 2014 86
Amyotrophic Lateral Sclerosis - Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2014 87
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H1 2014 88
Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corporation, H1 2014 89
Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H1 2014 90
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H1 2014 91
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2014 92
Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H1 2014 93
Amyotrophic Lateral Sclerosis - Pipeline by California Stem Cell, Inc., H1 2014 94
Amyotrophic Lateral Sclerosis - Pipeline by Varinel, Inc., H1 2014 95
Amyotrophic Lateral Sclerosis - Pipeline by ExSAR Corporation, H1 2014 96
Amyotrophic Lateral Sclerosis - Pipeline by Stealth Peptides Inc., H1 2014 97
Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H1 2014 98
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 99
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2014 100
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H1 2014 101
Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H1 2014 102
Amyotrophic Lateral Sclerosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2014 103
Amyotrophic Lateral Sclerosis - Pipeline by Bionure, H1 2014 104
Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 105
Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 106
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H1 2014 107
Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2014 108
Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H1 2014 109
Amyotrophic Lateral Sclerosis - Pipeline by Cellular Biomedicine Group, Inc., H1 2014 110
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H1 2014 111
Assessment by Monotherapy Products, H1 2014 112
Number of Products by Stage and Target, H1 2014 115
Number of Products by Stage and Mechanism of Action, H1 2014 119
Number of Products by Stage and Route of Administration, H1 2014 123
Number of Products by Stage and Molecule Type, H1 2014 126
Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H1 2014 334
Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2014 387
Amyotrophic Lateral Sclerosis - Discontinued Products, H1 2014 389
List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2014 25
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 34
Comparative Analysis by Late Stage Development, H1 2014 37
Comparative Analysis by Clinical Stage Development, H1 2014 38
Comparative Analysis by Early Stage Products, H1 2014 39
Assessment by Monotherapy Products, H1 2014 112
Number of Products by Top 10 Target, H1 2014 113
Number of Products by Stage and Top 10 Target, H1 2014 114
Number of Products by Top 10 Mechanism of Action, H1 2014 117
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 118
Number of Products by Top 10 Route of Administration, H1 2014 121
Number of Products by Stage and Top 10 Route of Administration, H1 2014 122
Number of Products by Top 10 Molecule Type, H1 2014 124
Number of Products by Stage and Top 10 Molecule Type, H1 2014 125
